Compare Nutrien Ltd (NTR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs TransMedics Group Inc — how do they compare? Nutrien Ltd trades at $81 (market cap $38.66B), while TransMedics Group Inc trades at $86.5 (market cap $3.00B). The key difference: Nutrien Ltd is far larger — about 12.9× TransMedics Group Inc's market cap, and Nutrien Ltd pays a 2.73% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NTR | TMDX | |
|---|---|---|
Market Cap | $38.66B | $3.00B |
Sector | Basic Materials | Technology |
52-Week High | $83.94 | $150.42 |
52-Week Low | $53.64 | $61.99 |
Enterprise Value | $50.46B | $3.39B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $80.68, up 1.52% today, near the analyst high target of $81.00. The stock shows a bullish technical trend with strong moving averages, though RSI levels indicate overbought conditions. Recent Q2 2026 earnings missed EPS estimates but beat on revenue, driven by higher fertilizer prices. The company maintains a moderate buy consensus with 61% of analysts recommending buys, supported by institutional accumulation like BlackRock's $220.94 million purchase in Q2 2026.
Outlook remains positive due to structural advantages in North American nitrogen assets and long-term agricultural demand, but risks include cyclical earnings, sulfur cost pressures, and volume constraints. The current price above the $76.17 consensus target suggests limited near-term upside, requiring monitoring of Q3 2026 results and cost management.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
